Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33

NewAmsterdam Pharma (NASDAQ:NAMS) has been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $43.33.

A number of equities analysts recently weighed in on NAMS shares. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Scotiabank boosted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. HC Wainwright reissued a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS opened at $20.03 on Wednesday. The firm has a market capitalization of $2.20 billion, a PE ratio of -7.70 and a beta of -0.01. The business’s 50-day moving average price is $19.68 and its two-hundred day moving average price is $21.22. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. As a group, analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. The trade was a 90.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James N. Topper acquired 1,135 shares of the stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the purchase, the director now owns 3,013,569 shares of the company’s stock, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 19.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C boosted its holdings in NewAmsterdam Pharma by 378.4% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company’s stock worth $110,879,000 after purchasing an additional 3,412,590 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its position in shares of NewAmsterdam Pharma by 23.8% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock worth $409,052,000 after buying an additional 3,061,224 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of NewAmsterdam Pharma by 291.9% in the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock worth $102,763,000 after buying an additional 2,978,263 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of NewAmsterdam Pharma by 2,410.4% in the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company’s stock valued at $59,499,000 after acquiring an additional 2,222,900 shares in the last quarter. Finally, Capital International Investors purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $53,007,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.